References
- Schauben J L, Spillane J. Poison prevention. Pharmacist 1991; 16: 38–48, US
- Mrvos R, Dean B S, Krenzelok E P. Poison center funding - who should pay. J Toxicol Clin Toxicol 1994; 32: 503–508
- Litovitz T L, Clark L R, Soloway R A. 1993 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1994; 12: 546–584
- Tong T G, Soloway R A. Fiscal antidotes needed. J Toxicol Clin Toxicol 1994; 32: 509–511
- King W D, Palmisano P A. Poison control centers: can their value be measured. South Med J 1991; 84: 722–726
- Geller R J, Looser R W. Cost savings form poison center use by medical consumers. Vet Hum Toxicol 1985; 27: 521
- Schleich C, McIntire M. Poison control and definitive cost containment. Vet Hum Toxicol 1984; 26: 101–104
- Filandrinos D T, Zunker R J, Sioris L J. Costs incurred from unnecessary emergency department visits for treatment of poisonings. Vet Hum Toxicol 1993; 35: 323
- Landis N T. Poison center's plight gets national attention. Am J Hosp Pharm. 1994; 51: 1755–1761
- CDC. A framework for assessing the effectiveness of disease and injury prevention programs. MMWR 1992; 41: RR-3
- Gavett J W, Mushlin A I. Calculating the costs of training in primary care. Med Care 1986; 24: 301–312
- Slack M K, Dragalis J R. A production model as a framework for the interpretation of economic evaluations in pharmacy education. Am J Pharm Educ 1993; 57: 242–247
- Cost-Chrischilles E A. Effetiveness Analysis. Principles of Pharmacoeconomics, J L Bootman, R J Townsend, F McGhan. Harvey Whitney Books Company, Cincinnati 1991; 73–101
- Drummond M F, Stoddart G L, Torrance G W. Method for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford 1987; 74–111
- Gaspari K C. The use and misuse of cost-effectiveness analysis. Soc Sci Med 1983; 17: 1043–1046
- Eisenberg J M. Clinical Economics. A guide to the economic analysis of clinical practices. JAMA 1989; 262: 2879–2886
- Birch S, Gafni A. Cost effectiveness/utility analyses: do current decision rules lead us to where we want to be. J Health Econ 1992; 11: 279–296
- Kitz D S. Cost-Benefit Analysis. Principal of Pharmacoeconomics, J L Bootman, F J Townsend, W F McGhan. Harvey Whitney Books Company, Cincinnati 1991; 73–101